-1753361001450.webp&w=3840&q=75)
2025 NOSCM | What is New in EGFR and ALK NSCLC?
Overview
Dr. Julia Rotow updated on EGFR and ALK mutations, stressing the use of osimertinib and lorlatinib.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Julia Rotow, MD
Date of Release
July 24th, 2025
-1755990775594.webp&w=3840&q=75)
-1755990700517.webp&w=3840&q=75)